Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Neurosurg Pediatr. 2019 Mar 1;23(3):261–273. doi: 10.3171/2018.10.PEDS18377

TABLE 4.

Current experimental protocols for HGG and DIPG

Therapeutic Approach Study Design Clinical Trial Identification Limitations
Intratumoral administration of DNX-2401 (oncolytic adenovirus) Phase I DIPG only
Heat shock protein peptide complex-96 (HSPPC-96) vaccine Phase I HGG only
Intracavitary & intraventricular administration of IL13Rα-specific chimeric antigen receptor T cells Phase I HGG only
Convection-enhanced delivery of oncolytic poliovirus immunotherapy Phase I Recurrent HGG only
Convection-enhanced delivery of panobinostat (histone deacetylase inhibitor) nanoparticle formulation Phase I/II DIPG only
Treatment w/ oral ribociclib (CDK4/6 inhibitor) & everolimus (mTOR inhibitor) Phase I DIPG & HGG
Treatment w/ oral PTC596 (BMI-1 inhibitor) during irradiation Phase I DIPG & HGG
R1: erlotinib (EGFR inhibitor) vs dasatinib (PDGFRA inhibitor); R2: everolimus vs dasatinib; R3: erlotinib vs everolimus vs dasatinib; dasatinib only Phase II randomized DIPG only
Treatment w/ oral vorinostat (histone deacetylase inhibitor) & intravenous temsirolimus (mTOR inhibitor) Phase I DIPG only
Treatment w/ ONC201 (DRD2 inhibitor) alone or during RT Phase I DIPG & HGG
Treatment w/ oral abemaciclib during & after RT Phase I DIPG only
MRI-guided laser heat ablation followed by intravenous doxorubicin Pilot HGG only

BMI-1 = B cell–specific Moloney murine leukemia virus integration site 1; EGFR = epidermal growth factor receptor; PDGFRA = platelet-derived growth factor receptor A.